Olesoxime

Drug Profile

Olesoxime

Alternative Names: RG-6083; TRO-19622

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Trophos
  • Developer Roche; Trophos
  • Class Cholestenones; Neuroprotectants; Oximes; Small molecules
  • Mechanism of Action Apoptosis inhibitors; GABA A receptor modulators; Mitochondrial permeability transition pore modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Spinal muscular atrophy
  • Phase II Multiple sclerosis
  • Preclinical Huntington's disease
  • Discontinued Amyotrophic lateral sclerosis; Diabetic neuropathies; Neuropathic pain; Non-alcoholic steatohepatitis

Most Recent Events

  • 19 Nov 2015 Phase-II/III clinical trials in Spinal muscular atrophy (In adolescents, In adults, In children) in United Kingdom, Belgium (PO)
  • 19 Nov 2015 Phase-II/III clinical trials in Spinal muscular atrophy (In children, In adolescents, In adults) in Italy (PO) (EudraCT2015-001589-25)
  • 08 Jun 2015 Phase-II development for Spinal musclular dystrophy is ongoing in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top